Belite Bio, Inc
BLTE
$166.43
$1.861.13%
NASDAQ
| 09/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 47.38% | 27.64% | 110.42% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 26.30% | 12.92% | 35.58% | -- |
| Operating Income | -- | -26.30% | -12.92% | -35.58% | -- |
| Income Before Tax | -- | -14.28% | -5.13% | -26.86% | -- |
| Income Tax Expenses | -- | -33.33% | -50.00% | -50.00% | -- |
| Earnings from Continuing Operations | -- | -14.26% | -5.12% | -26.84% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -14.26% | -5.12% | -26.84% | -- |
| EBIT | -- | -26.30% | -12.92% | -35.58% | -- |
| EBITDA | -- | -26.15% | -12.69% | -35.42% | -- |
| EPS Basic | -- | 6.46% | 14.17% | -2.38% | -- |
| Normalized Basic EPS | -- | -144.65% | -94.76% | 9.24% | -- |
| EPS Diluted | -- | 6.46% | 14.17% | -2.38% | -- |
| Normalized Diluted EPS | -- | -144.65% | -94.76% | 9.24% | -- |
| Average Basic Shares Outstanding | -- | 21.53% | 22.50% | 22.50% | -- |
| Average Diluted Shares Outstanding | -- | 21.53% | 22.50% | 22.50% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |